JPRN-jRCT2080220925未知2 期
A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged 60 or more With Newly Diagnosed Acute Myeloid Leukaemia (AML)
适应症
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the followings
- •-Age at 75 years or more
- •-Adverse cytogenetics, eg as defined by the MRC Prognostic Groupings
- •-WHO performance status 3 or more
- •-Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
排除标准
- •-Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
- •-Administration of LDAC is clinically contraindicated
- •-Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
- •-Patients with blast crisis of chronic myeloid leukaemia
研究者
相似试验
进行中（未招募）
不适用
A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged = 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens. - NDEUCTR2009-010114-30-ITASTRAZENECA288
进行中（未招募）
不适用
A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged = 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimensMedDRA version: 9.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaAcute Myeloid LeukemiaEUCTR2009-010114-30-DEAstraZeneca AB420
进行中（未招募）
1 期
A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged = 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimensMedDRA version: 9.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaAcute Myeloid LeukemiaEUCTR2009-010114-30-FRAstraZeneca AB420
进行中（未招募）
1 期
A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged = 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimensMedDRA version: 9.1 Level: LLT Classification code 10000880 Term: Acute myeloid leukaemiaAcute Myeloid LeukemiaEUCTR2009-010114-30-GBAstraZeneca AB420
已完成
不适用
A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients with Advanced Solid TumoursCancer: Solid tumour (Malignant solid tumour)Solid tumourCancerNL-OMON40586Astra Zeneca15